Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Matthew Powell; Oleksandr Zub; Lucy Gilbert; Anthoula Koliadi; Lyndsay Willmott; Destin Black; Graziana Ronzino; Sudarshan Sharma; Martina Gropp-Meier; Lisa Landrum; et al.

doi:10.1016/j.ygyno.2026.01.779

Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Matthew Powell, Oleksandr Zub, Lucy Gilbert, Anthoula Koliadi, Lyndsay Willmott, Destin Black, Graziana Ronzino, Sudarshan Sharma, Martina Gropp-Meier, Lisa Landrum, …

Gynecologic oncology, Vol.208, pp.S65-S66

05/2026

: https://doi.org/10.1016/j.ygyno.2026.01.779

1

: Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
: Matthew Powell - Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, United States
Oleksandr Zub - Chernihiv Medical Center of Modern Oncology, Chernihiv Regional Council, Chernihiv, Ukraine
Lucy Gilbert - Research Institute of the McGill University Health Centre
Anthoula Koliadi - Uppsala University Hospital
Lyndsay Willmott - Arizona Center for Cancer Care, Phoenix, AZ, United States
Destin Black - Willis-Knighton Cancer Center
Graziana Ronzino - Ospedale Vito Fazzi
Sudarshan Sharma - Amita Health
Martina Gropp-Meier - Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
Lisa Landrum - Indiana University Health
et al.
: Gynecologic oncology, Vol.208, pp.S65-S66
: Elsevier Inc
: 991006271510302656
: Obstetrics & Gynecology
: English
: Journal article